US2011020350A1PendingUtilityA1
Contraceptives Based on SP22 and SP22 Antibodies
Individually held — no corporate assignee on recordPriority: Jan 29, 1996Filed: Jun 11, 2010Published: Jan 27, 2011
Est. expiryJan 29, 2016(expired)· nominal 20-yr term from priority
Inventors:Gary R. Klinefelter
Y10S530/806C07K 2317/34G01N 2800/367A61K 35/52A61P 15/16G01N 33/6893C07K 16/18C07K 2317/55A61K 2039/54Y10S424/811G01N 33/689A61K 39/0006A61P 15/00C07K 14/47A61P 15/18C07K 16/32A61K 38/00Y10S530/852C07K 2317/76A61K 39/00
31
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Oral, topical and injectable contraceptives, which are based on sperm protein 22 kDa (SP22) polypeptides and antibodies and infertility diagnostics are provided.
Claims
exact text as granted — not AI-modified1 . A pharmaceutical composition comprising an effective anti-fertility amount of an antibody that binds to SP22 (SEQ ID NO: 2) and a pharmaceutically acceptable carrier.
2 . The pharmaceutical composition of claim 1 , wherein the antibody binds to amino acids 34-48 of SEQ ID NO: 2.
3 . The pharmaceutical composition of claim 1 , wherein the antibody binds to amino acids 47-102 of SEQ ID NO: 2.
4 . The pharmaceutical composition of claim 1 , wherein the antibody binds to amino acids 43-57 of SEQ ID NO: 2.
5 . The pharmaceutical composition of claim 1 , wherein the antibody binds to amino acids 58-72 of SEQ ID NO: 2.
6 . The pharmaceutical composition of claim 1 , wherein the antibody binds to amino acids 88-102 of SEQ ID NO: 2.
7 . The pharmaceutical composition of claim 1 , wherein the antibody binds to amino acids 118-132 of SEQ ID NO: 2.
8 . The pharmaceutical composition of claim 1 , wherein the antibody binds to amino acids 136-150 of SEQ ID NO: 2.
9 . The pharmaceutical composition of claim 1 , wherein the antibody binds to amino acids 160-174 of SEQ ID NO: 2.
10 . The pharmaceutical composition of claim 1 , which is within a cream, lotion, gel, foam, sponge, suppository or lubricant.
11 . The pharmaceutical composition of claim 10 , which is administered with an applicator.
12 . The pharmaceutical composition of claim 1 , which further comprises a second anti-fertility agent, an anti-fungal agent, an anti-bacterial agent, an anti-viral agent.
13 . The pharmaceutical composition of claim 12 , in which the second spermicidal agent is nonoxynol-9.
14 . A method of preventing conception, comprising contacting male ejaculate, prior to contact with a female egg, with an effective anti-fertility amount of a pharmaceutical composition, which comprises an antibody that binds to SP22 (SEQ ID NO:2) and a pharmaceutically acceptable carrier.
15 . The method of claim 14 , wherein the pharmaceutical composition is applied within the female's vagina.
16 . The method of claim 15 , wherein the pharmaceutical composition is in a suppository or applied using an applicator.
17 . The method of claim 15 , wherein the pharmaceutical composition is on a condom, diaphragm, cap, or sponge.
18 . A kit comprising an applicator and a pharmaceutical composition of claim 1 .
19 . A vaccine comprising an SP22 (SEQ ID NO: 2) polypeptide and a pharmaceutically acceptable carrier.
20 . The vaccine of claim 19 , wherein the SP22 polypeptide is comprised of amino acids 34-48 of SEQ ID NO: 2.
21 . The vaccine of claim 19 , wherein the SP22 polypeptide is comprised of amino acids 43-57 of SEQ ID NO: 2.
22 . The vaccine of claim 19 , wherein the antibody binds to amino acids 47-102 of SEQ ID NO: 2.
23 . The vaccine of claim 19 , wherein the SP22 polypeptide comprises of amino acids 88-102 of SEQ ID NO: 2.
24 . The vaccine of claim 19 , wherein the SP22 polypeptide comprises of amino acids 118-132 of SEQ ID NO: 2.
25 . The vaccine of claim 19 , wherein the SP22 polypeptide comprises of amino acids 136-150 of SEQ ID NO: 2.
26 . The vaccine of claim 19 , wherein the SP22 polypeptide comprises of amino acids 160-174 of SEQ ID NO: 2.
27 . The vaccine of claim 19 , which is formulated into a pill, tablet, capsule, suppository, lozenge, granule, powder or syrup.
28 . The vaccine of claim 19 , wherein the vaccine is within an injectable formulation.
29 . The vaccine of claim 19 , which further comprises an adjuvant.
30 . The vaccine of claim 29 , wherein the adjuvant is the Synervax adjuvant.
31 . The method of contraception comprising administering to a subject an effective amount of the vaccine composition of claim 19 to stimulate production of antibodies that are immunologically reactive against SP22 protein.
32 . The method of claim 31 , wherein the subject is male.
33 . The method of claim 31 , wherein the subject is female.
34 . The method of claim 31 , wherein the vaccine composition is administered orally, intravenously, intramuscularly, subcutaneously, intranasally or intravaginally.
35 . A method for detecting infertility in a male subject comprising detecting the SP22 level of the male subject's sperm, wherein a decreased level of SP22 relative to the normal level indicates that the male subject is infertile.
36 . The method of claim 35 , wherein the level of SP22 is determined using an immunoassay.
37 . The method of claim 36 , wherein the immunoassay is a lateral flow immunoassay.
38 . The method of claim 36 , wherein the immunoassay is a flow-through immunoassay.
39 . A method for monitoring fertility status in a subject undergoing SP22 vaccination comprising detecting SP22 antibody level in said subject, wherein an increased level of SP22 antibody indicates that the subject is protected against fertilization.
40 . The method of claim 39 , wherein the level of SP22 antibodies is determined using an immunoassay.Join the waitlist — get patent alerts
Track US2011020350A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.